Better Growth Stock: Teladoc vs. Hims & Hers
Healthcare is big business, especially in the United States, where the average person spends $12,530 on healthcare annually. Big markets attract innovation, and telehealth became a hot topic during the pandemic. Telehealth companies like Teladoc Health (NYSE: TDOC) and Hims & Hers Health (NYSE: HIMS) saw big share price bumps, but have since fallen to multi-year lows over the past 18 months.
Now that the dust is clearing following COVID-19, which is the better growth stock for the long haul? After digging into the numbers, the answer might surprise you.
Teladoc is a leading telehealth platform that conducts millions of virtual visits each year (about 18 million over the past year). The company thrived during COVID-19 lockdowns when patients were pushed to adopt digital care to avoid in-person office visits. But the company is more than a video call with a doctor; it acquired Livongo for $18.5 billion, integrating its chronic care and data monitoring technology to build what Teldadoc calls Primary 360, whole-person care that lets patients receive primary and personalized care through a smartphone app.
Source Fool.com
